29693
document
Desmopressin in the treatment of nocturia : a double-blind , placebo-controlled study . OBJECTIVES To investigate efficacy , safety , and impact on quality of sleep of desmopressin in the treatment of nocturia . METHODS Adults aged > or =18 yr with nocturia ( > or =2 voids/night ) received desmopressin tablets ( 0.1 , 0.2 , or 0.4 mg ) during a 3-wk dose-titration period . Patients should show sufficient response during the dose-titration period ( > or =20 % reduction in nocturnal diuresis ) and a return of nocturnal diuresis to > or =80 % of baseline levels during washout . Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo . RESULTS 127 patients were randomised to either desmopressin ( n=61 ) or placebo ( n=66 ) . Twenty ( 33 % ) desmopressin-treated patients compared with seven ( 11 % ) placebo-treated patients showed a clinical response , defined as a > or =50 % reduction in the number of nocturnal voids compared with baseline ( p=0.0014 ) . Compared with placebo , desmopressin resulted in a significant reduction in the mean number of nocturnal voids ( 39 % reduction with desmopressin vs. 15 % with placebo ; absolute difference -0.84 , p < 0.0001 ) and duration of the first sleep period ( prolonged by 108 min with desmopressin vs. 41 min with placebo ; p < 0.0001 ) . Quality of sleep was also improved with desmopressin versus placebo ( statistically significant for one of the two parameters evaluated ) . Adverse events were mainly mild . CONCLUSIONS Oral desmopressin tablets provide an effective and well-tolerated treatment for nocturia . Compared with placebo , nocturnal voiding frequency is reduced , duration of the first sleep period is increased , and sleep quality may be improved .
29694
Intervention_Pharmacological
Desmopressin
29695
Intervention_Pharmacological
desmopressin
29696
Intervention_Pharmacological
desmopressin
29697
Intervention_Pharmacological
desmopressin
29698
Intervention_Control
placebo
29699
Intervention_Pharmacological
desmopressin
29700
Intervention_Pharmacological
placebo
29701
Intervention_Control
desmopressin-treated
29702
Intervention_Control
placebo-treated
29703
Intervention_Pharmacological
desmopressin
29704
Intervention_Pharmacological
desmopressin
29705
Intervention_Pharmacological
placebo
29706
Intervention_Pharmacological
desmopressin
29707
Intervention_Pharmacological
placebo
29708
Intervention_Pharmacological
desmopressin
29709
Intervention_Pharmacological
placebo
29710
Intervention_Pharmacological
desmopressin
29711
Intervention_Pharmacological
placebo
29712
Outcome_Other
efficacy , safety
29713
Outcome_Physical
quality of sleep
29714
Outcome_Physical
number of nocturnal voids
29715
Outcome_Physical
mean number of nocturnal voids
29716
Outcome_Physical
duration of the first sleep period
29717
Outcome_Physical
Quality of sleep
29718
Outcome_Adverse-effects
Adverse events
29719
Outcome_Physical
nocturnal voiding frequency
29720
Outcome_Physical
sleep quality
29721
Participant_Condition
nocturia :
29722
Participant_Age
Adults aged > or =18 yr with nocturia ( > or =2 voids/night )